Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
6/3/2026, 12:00:00 AM
Johnson & Johnson announced on June 3, 2026, that its monoclonal antibody, nipocalimab, met the primary endpoint in the Phase 2 JASMINE study for SLE; positive clinical data for a major pipeline candidate is estimated to have a 5-10% market impact, expected.
Korean Translation
2026년 6월 3일, Johnson & Johnson은 니포칼리맙의 2상 JASMINE 연구에서 1차 평가변수를 충족했다고 발표함. 주요 파이프라인의 긍정적인 임상 데이터는 5-10%의 시장 영향을 미칠 것으로 예상됨.
Related Recent Events
Ambu A/S (AMBUB) · Earnings Release
Q3 2025/26 earnings release scheduled. (Low importance estimated for a routine scheduled event).
8/26/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
Q2 2026 earnings results and conference call for July 29, 2026, before market open scheduled
7/29/2026, 12:00:00 AM
Integer Holdings Corp (ITGR) · Earnings Release
Analysts forecast the next quarterly earnings release for 2026-07-23 estimated. Estimated Medium importance as earnings reports typically drive significant price volatility.
7/23/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet Q2 2026 earnings release scheduled for July 22, 2026, with analysts forecasting EPS of approximately $2.85-$2.87 forecasted.
7/22/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.
7/16/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM